Earnings ·
Kalaris Therapeutics reported financial results for the quarter ended June 30, 2026
KLRSKalaris Therapeutics, Inc.
Kalaris Therapeutics reported financial results for the quarter ended June 30, 2026. The company incurred a net loss of $11.5 million and spent $9.0 million on research and development, compared to an $8.4 million R&D expense in the prior year period. General and administrative expenses decreased to $3.4 million from $3.8 million. As of June 30, 2026, Kalaris held $93.5 million in cash, cash equivalents, and marketable securities, which management expects will fund operations through the fourth quarter of 2027. The company is currently dosing patients in its Phase 1b/2 study of TH103 for neovascular Age-related Macular Degeneration, with preliminary data anticipated in the first half of 2027. Kalaris Therapeutics operates as a clinical-stage biopharmaceutical company dedicated to developing treatments for prevalent retinal diseases.